Einträge von Riederer, Peter auf dem Publikationsserver

Thome, Johannes, Ehlis, Ann-Christine , Fallgatter, Andreas J., Krauel, Kerstin, Lange, Klaus W., Riederer, Peter, Romanos, Marcel, Taurines, Regina, Tucha, Oliver, Uzbekov, Marat und Gerlach, Manfred (2012) Biomarkers for attention-deficit/hyperactivity disorder (ADHD). A consensus report of the WFSBP task force on biological markers and the World Federation of ADHD. The World Journal of Biological Psychiatry 13 (5), S. 379-400. Volltext nicht vorhanden.

Luckhaus, Christian, Spiegler, Christian, Ibach, Bernd, Fischer, Peter, Wichart, Ildiko, Sterba, Nadine, Gatterer, Gerald, Rainer, Michael, Jungwirth, Susanne, Huber, Klaus, Tragl, Karl H., Grünblatt, Edna, Riederer, Peter und Sand, Philipp G. (2006) Estrogen Receptor β Gene (ESRβ) 3′-UTR Variants in Alzheimer Disease. Alzheimer Disease & Associated Disorders 20 (4), S. 322-323. Volltext nicht vorhanden.

Kavvadias, Dominique, Sand, Philipp , Youdim, Kuresh A, Qaiser, M Zeeshan, Rice‐Evans, Catherine, Baur, Roland, Sigel, Erwin, Rausch, Wolf‐Dieter, Riederer, Peter und Schreier, Peter (2004) The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood–brain barrier and exhibits anticonvulsive effects. British Journal of Pharmacology 142 (5), S. 811-820. Volltext nicht vorhanden.

Lange, Klaus W., Kornhuber, J. und Riederer, Peter (1994) GLUTAMATERGIC MECHANISMS IN THE BRAIN IN MOVEMENT-DISORDERS AND SCHIZOPHRENIA. Neuropsychiatrie 8 (2), S. 107-119. Volltext nicht vorhanden.

Lange, Klaus W. und Riederer, Peter (1994) Glutamatergic drugs in Parkinson's disease. Life sciences 55 (25-26), S. 2067-2075.

Riederer, Peter, Lange, Klaus W. und Youdim, M. B. (1993) Recent advances in pharmacological therapy of Parkinson's disease. Advances in neurology 60, S. 626-635. Volltext nicht vorhanden.

Lange, Klaus W., Löschmann, P. A., Sofic, E., Burg, M., Horowski, R., Kalveram, K. T., Wachtel, H. und Riederer, Peter (1993) The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates. Naunyn-Schmiedeberg's archives of pharmacology 348 (6), S. 586-592.

Riederer, Peter, Lange, Klaus W., Kornhuber, J. und Danielczyk, W. (1992) Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia. Arzneimittel-Forschung 42 (2A), S. 265-268.

Lange, Klaus W., Youdim, M. B. und Riederer, Peter (1992) Neurotoxicity and neuroprotection in Parkinson's disease. Journal of neural transmission. Supplementum supl. 38, S. 27-44.

Riederer, Peter und Lange, Klaus W. (1992) Pathogenesis of Parkinson's disease. Current opinion in neurology and neurosurgery 5 (3), S. 295-300.

Sofic, E., Lange, Klaus W., Jellinger, K. und Riederer, Peter (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neuroscience letters 142 (2), S. 128-130.

Riederer, Peter, Lange, Klaus W., Kornhuber, J. und Jellinger, K. (1991) Glutamate receptor antagonism: neurotoxicity, anti-akinetic effects, and psychosis. Journal of neural transmission. Supplementum supl. 34, S. 203-210.

Riederer, Peter, Lange, Klaus W., Kornhuber, J. und Danielczyk, W. (1991) Pharmacotoxic psychosis after memantine in Parkinson's disease. Lancet 338 (8773), S. 1022-1023.